Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: A naturalistic study with drug plasma levels

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 14, 2007, Pages 2207-2213

  Mauri, Massimo C ^a   Volonteri, Lucia S ^a   Fiorentini, Alessio ^a   Pirola, Rodolfo ^b   Bareggi, Silvio R ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acute treatment; Plasma levels; Psychotic disorders; Quetiapine

Indexed keywords

CANNABIS; COCAINE; QUETIAPINE;

ADULT; AGED; ARTICLE; BORDERLINE STATE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; CORRELATION COEFFICIENT; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HAMILTON SCALE; HOSPITAL PATIENT; HUMAN; INTERVIEW; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BORDERLINE PERSONALITY DISORDER; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOSES, SUBSTANCE-INDUCED; SCHIZOPHRENIA; TIME FACTORS;

EID: 35548984003     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.14.2207     Document Type: Article

References (44)

1. GEFVERT O, LUNDBERG T, WIESELGREN IM et al.: D2 and 5-HT2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. (2001) 11:105-110.
2. DE VANE CL, NEMEROFF CB: Clinical pharmacokinetics of quetiapine. Clin. Pharmacokinet. (2001) 40:509-522.
3. HELLEWELL JSE, CAMERON HANDS D, MCKELLAR J: Seroquel: an effective atypical antipsychotic with no greater EPS than placebo across the full dose range. Schizophr. Res. (1998) 29:154.
4. GUNASEKARA NS, SPENCER CM: Quetiapine. A review of its use in schizophrenia. CNS Drugs (1998) 9:325-340.
5. SMALL JG, HIRSCH SR, ARVANTIS LA et al.: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry (1997) 54:549-557.
6. ARVANTIS LA, MILLER BG: Multiple fixed doses of seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The seroquel trial 13 study group. Biol. Psychiatry (1997) 42:233-246.
7. BORISON RI, ARVANTIS LA, MILLER BG: ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. US Seroquel group. J. Clin. Psychopharmacol. (1996) 16:158-169.
8. PEUSKENS J, LINK CGC: A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr. Scand. (1997) 96:265-273.
9. COPOLOV DL, LINK CGC, KOWALCYK B: A multicentre, double-blind randomized comparison of quetiapine and haloperidol in schizophrenia. Psychol. Med. (2000) 30:95-105.
10. SCHULZ SC, THOMPSON R, BRECHER M: The efficacy of quetiapine vs. haloperidol and placebo: a meta-analytic study of efficacy. Schizophr. Res. (2003) 62:1-12.
11. TANDON R, JIBSON MD: Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology (2003) 28(Suppl. 1):9-26.
12. CHENGAPPA KN, GOLDSTEIN JM, GREENWOOD M et al.: A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia. Clin. Ther. (2003) 25:530-541.
13. CHENGAPPA KN, EBELING T, KANG JS et al.: Clozapine reduces severe self-mutilation and aggression in psychotic patients with borderline personality disorder. J. Clin. Psychiatry (1999) 60:477-484.
14. KHOUZAM HR, DONNELLY NJ: Remission of self-mutilation in a patient with borderline personality disorder during risperidone therapy. J. Nerv. Ment. Dis. (1997) 185:348-349.
15. ZANARINI MC, FRANKENBURG FR: Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo controlled pilot study. J. Clin. Psychiatry (2001) 62:849-854.
16. ZANARINI MC, FRANKENBURG FR, PARACHINI EA: A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J. Clin. Psychiatry (2004) 65:903-904.
17. NICKEL MK, MUEHLBACHER M, NICKEL C et al.: Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry (2006) 163(5):833-838.
18. ADITYANJEE, SCHULZ SC: Clinical use of quetiapine in disease states other than schizophrenia. J. Clin. Psychiatry (2002) 63(Suppl. 16):32-38.
19. HILGER E, BARNAS C, KASPER S: Quetiapine in the treatment of borderline personality disorder. World J. Biol. Psychiatry (2003) 4:42-44.
20. VILLENEUVE E, LEMELIN S: Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J. Clin. Psychiatry (2005) 66(10): ] 298-1303.
21. PERRELLA C, CARRUS D, COSTA E, SCHIFANO F: Quetiapine for the treatment of borderline personality disorder; an open-label study. Prog. NeuropsychopharmacoL Biol. Psychiatry (2007) 31(1):158-163.
22. ALBANESE MJ: Safety and efficacy of risperidone in substance abusers with psychosis. Am. J. Addict. (2001) 10:190-191.
23. SATTAR SP, GRANT K, BHATIA S, PETTY F: Potential use of olanzapine in treatment of substance dependence disorders. J. Clin. Psychopharmacol. (2003) 23:413-415.
24. SATTAR SP, BHATIA SC: Olanzapine for cocaine cravings and relapse prevention. J. Clin. Psychiatry (2003) 64:969.
25. ZIMMET SV, STROUS RD, BURGESS ES: Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J. Clin. Psychopharmacol. (2000) 20:94-98.
26. MISRA L, KOFOED L: Risperidone treatment of methamphetamine psychosis. Am. J. Psychiatry (1997) 154:1170.
27. MISRA LK, KOFOED L, OESTERHELD J, RICHARDS G: Olanzapine treatment of methamphetamine psychosis. J. Clin. Psychopharmacol. (2000) 20:393-394.
28. SATTAR SP, BHATIA SC, PETTY F: Potential benefits of quetiapine in the treatment of substance dependence disorders. J. Psychiatry Neurosci. (2004) 29:452-457.
29. FABRE JR, ARVANITIS L, PULTZ J et al.: ICI 204,636, a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin. Ther. (1995) 17:366-378.
30. AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC (2000).
31. OVERALL JE, GORHAM DR: The brief psychiatric rating scale. Psychol. Rep. (1962) 10:799-812.
32. KAY SR, FISZBEIN A, OPLER LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. (1987) 13:261-276.
33. HAMILTON M: A rating scale for depression. J. Neurol. Neurosurg. Psychiatry (1960) 23:56-62.
34. SIMPSON RM, ANGUS JSW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand. (1970) 212:11-19.
35. MANDRIOLI R, FANALI S, FERRANTI A, RAGGI MA: HPLC analysis of the novel antipsychotic drug quetiapine in human plasma. J. Pharm. Biomed. Anal. (2002) 30:969-977.
36. HELLEWELL J, CANTILLION M, MCKELLAR M: "Seroquel": efficacy in aggression, hostility and low mood of schizophrenia. Int. J. Neuropsychopharmacol. (1999) 2(Suppl. 1):S112.
37. SAJATOVIC M, MULLEN JA, SWEITZER DE: Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J. Clin. Psychiatry (2002) 63:1156-1163.
38. GOLDSTEIN J: Quetiapine fumarate (seroquel): a new atypical antipsychotic. Drug Today (1999) 35:193-210.
39. CHEER SM, WAGSTAFF AJ: Quetiapine. A review of its use in the management of schizophrenia. CNS Drugs (2000) 18:173-199.
40. JONES AM, RAK IW, RANIWALLA J et al.: Weight changes in patients treated with 'Seroquel' (quetiapine). Schizophr. Res. (2000) 41:83.
41. DAVIS PC, WONG J, GEVFERT O: Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J. Pharm. Biomed. Anal. (1999) 20:271-282.
42. THYRUM PT, FABRE LF, WONG YWJ: Multiple dose pharmacokinetics of ICI 204,636 in schizophrenic men and women. Psychopharmacol. Bull. (2003) 32:525.
43. THYRUM PT, WONG YW, YEH C: Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog. Neuropsychopharmacol. Biol. Psychiatry (2000) 24:521-533.
44. WONG J, EWING B, THYRUM P et al.: Kinetics of Seroquel in hepatic and renal insufficiency. 10th World Congress of Psychiatry. Madrid 2 (1996):300.